Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series E
Pathos AI is firing on all cylinders. The technology and drug development company told Endpoints News that it signed a major antibody-drug conjugate (ADC) deal with a Chinese biotech and teamed up with its CEO's ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.